Ambu maintains investment level for R&D despite narrower focus
The Danish medtech company’s new CEO Britt Meelby Jensen wants to develop fewer but better products through a new strategy – even so, the R&D budget won’t be lowered.
by ulrich quistgaard, translated by daniel pedersen
Ambu will continue to spend as much money as it does now on researching and developing new products – despite having just announced a new strategy, dubbed Zoom In, meaning the company will develop fewer endoscopy products in coming years.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.